Open AccessDarolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial
Author(s) -
Matthew R. Smith,
Maha Hussain,
Fred Saad,
Karim Fizazi,
Cora N. Sternberg,
David Crawford,
Jan Manarite,
David Muslin,
Thomas Farrington,
Bertrand Tombal
Publication year - 2022
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2022-0433
Subject(s) - docetaxel , medicine , prostate cancer , oncology , enzalutamide , placebo , androgen deprivation therapy , clinical trial , cancer , androgen receptor , alternative medicine , pathology
This is a summary of a publication about the ARASENS trial, which was published in the New England Journal of Medicine in February 2022. The trial includes 1,306 men with a type of prostate cancer called metastatic, hormone-sensitive prostate cancer (also called mHSPC). In the trial, researchers wanted to learn if combining a treatment called darolutamide (also known by the brand name Nubeqa ® ) with two other medicines called androgen deprivation therapy (also called ADT) and docetaxel (brand name Taxotere ® ) could help treat patients with mHSPC better than placebo plus ADT and docetaxel. ADT with docetaxel is a treatment used for patients with mHSPC. Darolutamide is an approved treatment for a different type of prostate cancer called non-metastatic, castration-resistant prostate cancer (also called nmCRPC).